NCT05943834 Early Detection of Alzheimer's Disease and Affective Disorders by Automated Voice and Speech Analysis (PLATA)
| NCT ID | NCT05943834 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Condition | Neurocognitive Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-07-13 |
| Primary Completion | 2027-10-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2023-07-13 with a primary completion date of 2027-10-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PLATA aims to develop an algorithm to identify vocal biomarkers of Alzheimer's dementia. Using data collected as part of routine care, speech patterns will be compared to known biomarkers of Alzheimer's disease, such as amyloid 1-42 and p-Tau in CSF (cerebrospinal fluid). If biomarkers of speech can be identified in Alzheimer's disease, it is possible that patients and research participants will no longer need to undergo need to undergo the intensive and invasive baseline biomarker methods currently used, such as lumbar punctures and PET scans.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 50 years * Diagnosis relevant biomarker and neuropsychological data already available * Cognitively healthy to very mild dementia (CDR score max. 0.5) * Sufficient knowledge of the study language to understand study information, non opposition form,and questionnaires * Expression of non opposition Exclusion Criteria: * Hearing problems * Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code
Contact & Investigator
Eric ETTORE, MD
PRINCIPAL INVESTIGATOR
Centre Hospitalier Universitaire de Nice
Frequently Asked Questions
Who can join the NCT05943834 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 100 Years, studying Neurocognitive Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05943834 currently recruiting?
Yes, NCT05943834 is actively recruiting participants. Contact the research team at ettore.e@chu-nice.fr for enrollment information.
Where is the NCT05943834 trial being conducted?
This trial is being conducted at Nice, France.
Who is sponsoring the NCT05943834 clinical trial?
NCT05943834 is sponsored by Centre Hospitalier Universitaire de Nice. The principal investigator is Eric ETTORE, MD at Centre Hospitalier Universitaire de Nice. The trial plans to enroll 100 participants.